Vectorized anti-tnf-alpha inhibitors for ocular indications

A composition for use in treating non-infectious uveitis in a human subject in need thereof, wherein a therapeutically effective amount of the composition is administered subretinally, intravitreally, intranasally, intracamerally, suprachoroidally, or systemically to the subject, said composition comprising a recombinant AAV comprising a viral capsid and an expression cassette flanked by ITR sequences, wherein the expression cassette comprises a transgene encoding a TNFα inhibitor operably linked to one or more regulatory sequences that control expression of the transgene in a human ocular tissue cell

A method of administering an anti-TNFα antibody or antigen binding fragment thereof to a non-human animal, said method comprising subretinally, intravitreally, intranasally, intracamerally, suprachoroidally, or systemically administering to the non-human animal a therapeutically effective amount of a composition comprising a recombinant AAV comprising a viral capsid and an artificial genome comprising an expression cassette flanked by AAV inverted terminal repeats (ITRs), wherein the expression cassette comprises a transgene encoding a heavy chain and a light chain of a substantially full-length or full-length 8C11 mAb, or an antigen-binding fragment thereof, operably linked to one or more regulatory sequences that control expression of the transgene in a human ocular tissue cell.

A host cell comprising:

• a plasmid comprising a cis expression cassette flanked by AAV ITRs, wherein the cis expression cassette comprises comprising a transgene encoding an scFv form of adalimumab or a substantially full-length or full-length or antigen-binding fragment of 8C11, operably linked to one or more regulatory sequences that promote expression of the transgene in human ocular tissue cells.